The latter molecular modification has previously been shown to confer protection to p53 against degradation by Mdm2 and thereby to interfere with the radiosensitivity and/or chemosensitivity of tumour cells (Shieh et al, 1997; Gao et al, 1999). The gene discussed is TP53; the disease is neoplasm.